[1] Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023 [J]. CA Cancer J Clin, 2023, 73(1): 17-48. [2] Chen SH, Hsiao SY, Chang KY, et al. New insights into oral squamous cell carcinoma: From clinical aspects to molecular tumorigenesis [J]. Int J Mol Sci, 2021, 22(5):2252. [3] Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma [J]. Nat Rev Dis Primers, 2020, 6(1): 92. [4] Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods [J]. Int J Cancer, 2019, 144(8): 1941-1953. [5] Ling Z, Cheng B, Tao X. Epithelial-to-mesenchymal transition in oral squamous cell carcinoma: Challenges and opportunities [J]. Int J Cancer, 2021, 148(7): 1548-1561. [6] Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease [J]. Cell, 2017, 168(6): 960-976. [7] Khan KH, Yap TA, Yan L, et al. Targeting the PI3K-AKT-mTOR signaling network in cancer [J]. Chin J Cancer, 2013, 32(5): 253-265. [8] Li X, Sun C, Chen J, et al. Suppression of FAM83D inhibits glioma proliferation, invasion and migration by regulating the AKT/mTOR signaling pathway [J]. Transl Oncol, 2022, 22: 101454. [9] Shi Z, Liu R, Lu Q, et al. UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKα2/mTOR pathway [J]. Int J Med Sci, 2021, 18(16): 3749-3758. [10] Liao H, Zhang L, Lu S, et al. KIFC3 promotes proliferation, migration, and invasion in colorectal cancer via PI3K/AKT/mTOR signaling pathway [J]. Front Genet, 2022, 13: 848926. [11] Tan Y, Wang Z, Xu M, et al. Oral squamous cell carcinomas: state of the field and emerging directions [J]. Int J Oral Sci, 2023, 15(1): 44. [12] Kondo S, Hirakawa H, Ikegami T, et al. Raptor and rictor expression in patients with human papillomavirus-related oropharyngeal squamous cell carcinoma [J]. BMC Cancer, 2021, 21(1): 87. [13] Zhu Y, Wang S, Niu P, et al. Raptor couples mTORC1 and ERK1/2 inhibition by cardamonin with oxidative stress induction in ovarian cancer cells [J]. PeerJ, 2023, 11: e15498. [14] Bhat GR, Hyole RG, Li J. Head and neck cancer: Current challenges and future perspectives [J]. Adv Cancer Res, 2021, 152: 67-102. [15] Yang H, Jiang X, Li B, et al. Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40 [J]. Nature, 2017, 552(7685): 368-373. [16] Bandres E, Agirre X, Ramirez N, et al. MicroRNAs as cancer players: potential clinical and biological effects [J]. DNA Cell Biol, 2007, 26(5): 273-282. [17] Bi G, Liang J, Zhao M, et al. miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways [J]. Mol Ther Nucleic Acids, 2022, 28: 366-386. [18] Toda H, Seki N, Kurozumi S, et al. RNA-sequence-based microRNA expression signature in breast cancer: tumor-suppressive miR-101-5p regulates molecular pathogenesis [J]. Mol Oncol, 2020, 14(2): 426-446. [19] Sun S, Wang J, Liu J, et al. MiR-302b suppresses tumor metastasis by targeting frizzled 6 in OSCC [J]. J Dent Res, 2021, 100(7): 739-745. [20] Wang Y, Jia RZ, Diao S, et al. miRNA-101 targets TGF-βR1 to retard the progression of oral squamous cell carcinoma [J]. Oncol Res, 2020, 28(2): 203-212. [21] Wang X, Zhou X, Zeng F, et al. miR-485-5p inhibits the progression of breast cancer cells by negatively regulating MUC1 [J]. Breast Cancer, 2020, 27(4): 765-775. |